7 completed, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 10 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial Faricimab, Sham - Central Serous Chorioretinopathy (CSC) | Phase 2 | Not yet recruiting | Singapore National Eye Centre | 50 | 2026-12-01 | 2026-07-02 |
| A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME) IBI302, Faricimab - Diabetic Macular Oedema | Phase 2 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 150 | 2025-04-24 | 2026-05-27 |
| Intravitreal Faricimab in Patients With Refractory Macular Edema Faricimab Injection - Age-Related Macular Degeneration | Phase 2 | Completed | University of Baghdad | 43 | 2024-09-10 | 2025-07-30 |
| Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients Faricimab - Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2024-03-01 | 2024-08-27 |
| Safety and Efficacy of Faricimab in Patients With NPDR Faricimab - Non-Proliferative Diabetic Retinopathy | Phase 2 | Completed | Greater Houston Retina Research | 179 | 2023-05-16 | 2026-03-20 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema RO7446603, Aflibercept, Faricimab - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Genentech, Inc. | 388 | 2022-06-22 | 2026-06-23 |
| A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab Faricimab - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 99 | 2020-11-25 | 2026-06-15 |
| Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration Faricimab, Ranibizumab, Sham Procedure - Neovascularization, Choroidal, Macular Degeneration, Age-Related | Phase 2 | Completed | Hoffmann-La Roche | 76 | 2017-01-27 | 2021-01-05 |
| A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema Faricimab, Ranibizumab - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 229 | 2016-04-27 | 2020-09-25 |
| A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization | Phase 2 | Completed | Hoffmann-La Roche | 273 | 2015-08-11 | 2020-11-12 |
Macular Degeneration (3) · Choroidal Neovascularization (2) · Central Serous Chorioretinopathy (1) · Retinal Vein Occlusion (1)
Hoffmann-La Roche (4) · Genentech, Inc. (1) · Greater Houston Retina Research (1) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Singapore National Eye Centre (1) · University of Baghdad (1)
United States (6) · China (3) · Argentina (1) · Canada (1) · Germany (1) · Iraq (1) · Italy (1) · Poland (1) · Puerto Rico (1) · United Kingdom (1)
Duaa J Kadhim (1) · Panpan Ye, doctor (1)
PMID 30905643, PMID 32729888, PMID 32729897, PMID 34201045, PMID 37422192, PMID 37868796, PMID 38758639, PMID 41587134, PMID 42058170